Peter J. Piliero

2.9k total citations · 1 hit paper
49 papers, 2.0k citations indexed

About

Peter J. Piliero is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Peter J. Piliero has authored 49 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Infectious Diseases, 24 papers in Virology and 12 papers in Emergency Medicine. Recurrent topics in Peter J. Piliero's work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (17 papers). Peter J. Piliero is often cited by papers focused on HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (17 papers). Peter J. Piliero collaborates with scholars based in United States, Canada and Germany. Peter J. Piliero's co-authors include Jacob Lalezari, Miklos Salgo, Steven Schnittman, Alexandra Thiry, Daniel R. Kuritzkes, John Delehanty, Mary O’Hearn, Jain Chung, Calvin Cohen and Joseph J. Eron and has published in prestigious journals such as New England Journal of Medicine, Neurology and Clinical Infectious Diseases.

In The Last Decade

Peter J. Piliero

47 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Keith Henry et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Peter J. Piliero

Since Specialization

Citations

This map shows the geographic impact of Peter J. Piliero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Piliero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Piliero more than expected).

Fields of papers citing papers by Peter J. Piliero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Piliero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Piliero. The network helps show where Peter J. Piliero may publish in the future.

Co-authorship network of co-authors of Peter J. Piliero

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Piliero. A scholar is included among the top collaborators of Peter J. Piliero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Piliero. Peter J. Piliero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients 2011 ·Drugs in R&D ·Mabrouk Elgadi, Peter J. Piliero	9
2	Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study 2010 ·Current HIV Research ·John D. Baxter, Laveeza Bhatti, Eoin Coakley, (unknown), (unknown), Richard Vinisko, Peter J. Piliero	3
3	Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone 2009 ·Drug and Alcohol Dependence ·R. Douglas Bruce, Frederick L. Altice, David E. Moody, (unknown), Wenfang B. Fang, John P. Sabo, (unknown), Peter J. Piliero, (unknown), Laurie Andrews, Gerald Friedland	18
4	Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anita Mathias, John E. Hinkle, Gong Shen, (unknown), Peter J. Piliero, Vanitha Sekar, (unknown), Frank Tomaka, Brian P. Kearney	19
5	Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients 2007 ·AIDS Research and Human Retroviruses ·Joseph Gathe, Gerald Pierone, Peter J. Piliero, Keikawus Arastéh, Rafael Rubio, Richard Lalonde, David A. Cooper, Adriano Lazzarin, Veronika Kohlbrenner, (unknown), John P. Sabo, Douglas L. Mayers	19
6	Ritonavir-Boosted Protease Inhibitors: Impact of Ritonavir on Toxicities in Treatment-Experienced Patients 2007 ·Journal of the Association of Nurses in AIDS Care ·Michael Sension, Peter J. Piliero	5
7	Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects 2006 ·AIDS ·Melanie Thompson, Edwin DeJesus, Gary Richmond, David A. Wheeler, John F. Flaherty, Peter J. Piliero, Andrea L. True, (unknown), Ying Zhang, (unknown), G. Diego Miralles, Indravadan H. Patel	7
8	Strategies for Initiating Combination Antiretroviral Therapy 2005 ·AIDS Patient Care and STDs ·Michael L. Tapper, Eric S. Daar, Peter J. Piliero, Kimberly Y. Smith, Corklin Steinhart	4
9	Atazanavir: A novel once-daily protease inhibitor 2004 ·Drugs of today ·Peter J. Piliero	9
10	Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers 2004 ·AIDS ·Mary Beth Wire, Charles H. Ballow, Sandra L. Preston, Craig W. Hendrix, Peter J. Piliero, Yu Lou, Daniel S. Stein	29
11	Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Peter J. Piliero	77
12	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America breakdown → 2003 ·New England Journal of Medicine ·Jacob Lalezari, Keith Henry, Mary O’Hearn, Joan Montaner, Peter J. Piliero, Benoît Trottier, Sharon Walmsley, Calvin Cohen, Daniel R. Kuritzkes, Joseph J. Eron, Jain Chung, Ralph DeMasi, (unknown), (unknown), John Delehanty, Miklos Salgo	716
13	Guillain‐Barre Syndrome Associated with Immune Reconstitution 2003 ·Clinical Infectious Diseases ·Peter J. Piliero, Douglas G. Fish, Sandra L. Preston, (unknown), Tosca Kinchelow, Miklos Salgo, Qian Jiang, George L. Drusano	54
14	Pharmacodynamics and clinical use of anti-HIV drugs 2003 ·Infectious Disease Clinics of North America ·Sandra L. Preston, Peter J. Piliero, George L. Drusano	4
15	Simplified Regimens for Treating HIV Infection and AIDS 2003 ·Journal of the American Academy of Nurse Practitioners ·Peter J. Piliero, (unknown)	6
16	Case report. Hepatitis B virus and HIV coinfection. 2002 ·PubMed ·Peter J. Piliero, (unknown)	10
17	Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens 2000 ·Journal of Correctional Health Care ·Calvin Cohen, Peter J. Piliero, (unknown)	1
18	Pulmonary Zygomycosis After Allogeneic Bone Marrow Transplantation 1995 ·Southern Medical Journal ·Peter J. Piliero, Robert L. Deresiewicz	6
19	Eastern Equine Encephalitis Presenting as Focal Neuroradiographic Abnormalities: Case Report and Review 1994 ·Clinical Infectious Diseases ·Peter J. Piliero, Joshua Brody, Amir A. Zamani, Robert L. Deresiewicz	12
20	Acute Uveitis Associated With Rifabutin Use in Patients With Human Immunodeficiency Virus Infection 1994 ·American Journal of Ophthalmology ·Deborah S. Jacobs, Peter J. Piliero, (unknown), (unknown), (unknown), Timothy Flanigan, (unknown), (unknown)	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact